Cite
Morimoto M, Numata K, Kondo M, et al. Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib. Hepatol Res. 2011;41(4):296-302doi: 10.1111/j.1872-034X.2011.00778.x.
Morimoto, M., Numata, K., Kondo, M., Hidaka, H., Takada, J., Shibuya, A., Kobayashi, S., Ohkawa, S., Okuse, C., Morita, S., Taguri, M., & Tanaka, K. (2011). Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib. Hepatology research : the official journal of the Japan Society of Hepatology, 41(4), 296-302. https://doi.org/10.1111/j.1872-034X.2011.00778.x
Morimoto, Manabu, et al. "Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib." Hepatology research : the official journal of the Japan Society of Hepatology vol. 41,4 (2011): 296-302. doi: https://doi.org/10.1111/j.1872-034X.2011.00778.x
Morimoto M, Numata K, Kondo M, Hidaka H, Takada J, Shibuya A, Kobayashi S, Ohkawa S, Okuse C, Morita S, Taguri M, Tanaka K. Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib. Hepatol Res. 2011 Apr;41(4):296-302. doi: 10.1111/j.1872-034X.2011.00778.x. Epub 2011 Feb 23. PMID: 21348907.
Copy
Download .nbib